A number of other analysts have also recently commented on PRAH. Goldman Sachs Group cut PRA Health Sciences from a buy rating to a neutral rating and dropped their price objective for the stock from $130.00 to $120.00 in a research report on Friday, January 10th. Wolfe Research upgraded PRA Health Sciences from a peer perform rating to an outperform rating and set a $123.00 price objective for the company in a research report on Thursday, November 14th. Zacks Investment Research cut PRA Health Sciences from a hold rating to a sell rating and set a $116.00 price objective for the company. in a research report on Tuesday, December 31st. Finally, Citigroup began coverage on PRA Health Sciences in a research report on Monday, January 6th. They set a neutral rating and a $120.00 price objective for the company. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company’s stock. PRA Health Sciences presently has a consensus rating of Hold and a consensus price target of $116.40.
Shares of PRAH stock opened at $104.74 on Friday. PRA Health Sciences has a fifty-two week low of $85.00 and a fifty-two week high of $115.50. The stock has a market cap of $6.54 billion, a P/E ratio of 26.65, a P/E/G ratio of 1.38 and a beta of 1.14. The business has a fifty day simple moving average of $107.83 and a 200-day simple moving average of $101.67. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 1.65.
Institutional investors and hedge funds have recently bought and sold shares of the business. Quadrant Capital Group LLC purchased a new stake in PRA Health Sciences in the 3rd quarter valued at about $38,000. Cullen Frost Bankers Inc. grew its holdings in PRA Health Sciences by 232.5% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 409 shares of the medical research company’s stock valued at $40,000 after buying an additional 286 shares during the period. CENTRAL TRUST Co grew its holdings in PRA Health Sciences by 20.5% in the 3rd quarter. CENTRAL TRUST Co now owns 792 shares of the medical research company’s stock valued at $79,000 after buying an additional 135 shares during the period. FNY Investment Advisers LLC purchased a new stake in PRA Health Sciences in the 4th quarter valued at about $122,000. Finally, Meeder Asset Management Inc. grew its holdings in PRA Health Sciences by 147.3% in the 3rd quarter. Meeder Asset Management Inc. now owns 1,667 shares of the medical research company’s stock valued at $165,000 after buying an additional 993 shares during the period. Institutional investors own 98.51% of the company’s stock.
About PRA Health Sciences
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
See Also: Trading based on a resistance level
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.